A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

NCT01375842 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

661

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumors
Hematologic Malignancies

Interventions

DRUG: Atezolizumab

Sponsor

Genentech, Inc.